KALV

KalVista Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website kalvista.com
Employees(FY) 118
ISIN US4834971032

Performance

-4.4%

-7.62%

-24.0%

-26.47%

-31.76%

YTD

-24.0%

Profile

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of KALV 2024-12-20

The stock's indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, while the Oscillators Score of 50 suggests a neutral stance, and the Technical Score of 30 reinforces the bearish outlook. This combination implies that the stock is currently facing significant selling pressure, wit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of KALV

Stock Rank

Recent News & Updates

2024-12-15 18:00
KalVista Appoints Jeb Ledell as Chief Operating Officer(Businesswire)
2024-12-04 17:30
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update(Businesswire)
2024-12-03 17:30
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-11-25 18:00
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors(Businesswire)
2024-11-11 17:30
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences(Businesswire)
2024-11-05 07:29
KalVista Secures $184M Financing for Sebetralstat Launch(TipRanks)
2024-11-05 06:30
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-11-04 17:30
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-11-04 11:35
KalVista Closes Royalty Financing Deal with DRI Healthcare, Prices $55 Million Offering(MT Newswires)
2024-11-04 08:28
DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat(MT Newswires)
2024-11-04 07:05
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million(Business Wire)
2024-11-04 07:00
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust(Business Wire)
2024-11-03 18:05
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million(Businesswire)
2024-11-03 18:00
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust(Businesswire)
2024-10-28 06:30
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology(Business Wire)
2024-10-27 18:30
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology(Businesswire)
2024-10-18 06:30
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)(Business Wire)
2024-10-17 18:30
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)(Businesswire)
2024-10-04 12:29
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum(Business Wire)
2024-10-04 00:29
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum(Businesswire)
2024-10-02 06:30
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-10-02 06:02
High Growth Tech Stocks To Watch In The United States(Simply Wall St.)
2024-10-01 18:30
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-09-30 08:49
KalVista Submits Marketing Applications for Angioedema Treatment Sebetralstat(MT Newswires)
2024-09-30 06:30
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema(Business Wire)
2024-09-29 18:30
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema(Businesswire)
2024-09-26 06:30
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)(Business Wire)
2024-09-25 18:30
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)(Businesswire)
2024-09-10 07:26
KalVista Pharmaceuticals Names Brian Piekos Finance Chief(MT Newswires)
2024-09-10 07:00
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference(Business Wire)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.